Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Halozyme Therapeutics Inc. Stories

2011-10-05 07:00:00

SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of patient dosing in a Phase 2 clinical trial with pegylated rHuPH20 (PEGPH20) in patients with stage IV previously untreated pancreatic cancer. This multi-center, international, randomized,...

2011-09-28 07:00:00

SAN DIEGO, Sept. 28, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today announced the commencement of a Phase 1/2 clinical trial with HTI-501 (rHuCAT-L) in women with moderate to severe edematous fibrosclerotic panniculopathy (also known as cellulite). (Logo:...

2011-09-22 07:00:00

SAN DIEGO, Sept. 22, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the JMP Securities Healthcare Conference in New York. The presentation is scheduled for Wednesday, September 28 at 8:30 a.m. EDT (5:30 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations...

2011-09-01 07:00:00

SAN DIEGO, Sept. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at two upcoming financial conferences, the William Blair Life Sciences Conference in New York and the Stifel Nicolaus Healthcare Conference in Boston. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The William Blair Life Sciences...

2011-08-12 07:00:00

SAN DIEGO, Aug. 12, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Wedbush 2011 Life Sciences Conference in New York. The presentation is scheduled for Wednesday, August 17 at 9:10 a.m. EDT (6:10 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section...

2011-08-05 07:00:00

SAN DIEGO, Aug. 5, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, cancer, dermatology and drug delivery markets, today reported financial results for the second quarter of 2011 and discussed recent business progress. "We continue to execute on our business strategy, with strong progress this quarter," said Gregory I. Frost, Ph.D., Halozyme's...

2011-08-01 07:00:00

SAN DIEGO, Aug. 1, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced it plans to report second quarter 2011 financial results on Friday, August 5, 2011 before the open of the financial markets. The announcement will be followed by a conference call with the investment community at 8:00 a.m. PDT (11:00 a.m. EDT), which will be simultaneously broadcast over...

2011-06-24 16:01:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced final results from a study in type 1 diabetes patients who receive their insulin treatment with a pump demonstrating that Aspart-PH20, a formulation of Halozyme's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog®, reduces the variability of insulin absorption and reduces post-meal glycemic excursions compared to NovoLog alone. Halozyme is...

2011-06-20 14:28:00

SAN DIEGO, June 20, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced three upcoming data presentations for it Ultrafast Insulin programs at the American Diabetes Association (ADA) 71st Scientific Sessions taking place June 24-28, 2011 at the San Diego Convention Center. (Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO) The presentations...

2011-06-02 06:30:00

SAN DIEGO, June 2, 2011 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that management will be presenting at the Jefferies 2011 Global Healthcare Conference in New York. The presentation is scheduled for June 9 at 11:00 a.m. EDT (8:00 a.m. PDT). To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the...